Related Experiment Video
Updated: Jul 2, 2026
06:00
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Stathmin 1: a novel therapeutic target for anticancer activity
Shushan Rana1, Phillip B Maples, Neil Senzer
1Gradalis, Inc., 2545 Golden Bear Drive, Suite 110, Carrollton, TX 75006, USA. srana@gradalisinc.com
Expert Review of Anticancer Therapy
|September 2, 2008
Summary
Stathmin 1 (STMN1) is a protein crucial for cell division. Its overexpression in many cancers suggests STMN1 is a promising therapeutic target for cancer treatment.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Stathmin 1 (STMN1) is a 19 kDa cytosolic phosphoprotein.
- It is the first discovered member of a family of microtubule-destabilizing proteins.
- STMN1 plays a critical role in mitotic spindle assembly and function.
Purpose of the Study:
- To review the role of STMN1 in cell proliferation and cancer.
- To summarize data supporting STMN1 as a therapeutic target in oncology.
- To provide rationale for the clinical manipulation of STMN1.
Main Methods:
- Literature review of existing data on STMN1.
- Analysis of STMN1 expression patterns in various cell types and malignancies.
- Evaluation of STMN1's role in cell cycle regulation and cancer progression.
Main Results:
- STMN1 is essential for mitosis progression in diverse cell types.
- Overexpression of STMN1 is observed across a wide spectrum of human cancers.
- STMN1 is upregulated in proliferating cells, including cancer cells, but rarely in non-proliferating cells.
Conclusions:
- STMN1 is frequently overexpressed in human malignancies.
- Its critical role in mitosis and cancer progression makes it a viable therapeutic target.
- Targeting STMN1 offers a potential strategy for novel cancer therapies.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:45Destabilization of Microtubules
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...